Introduction
============

Inflammation is a protective and tightly regulated immune response to tissue damage or pathogen invasion ([@B17]). In the central nervous system (CNS), this process is known as neuroinflammation and is characterized by the activation of the microglia and astrocytes population ([@B2]). The innate immune response is triggered upon the recognition of pathogen-associated molecular patterns (PAMPs), derived from invading pathogens, and danger-associated molecular patterns (DAMPs), induced as a result of endogenous stress, by pattern-recognition receptors (PRRs; [@B3]). Activation of PRRs by PAMPs or DAMPs triggers signaling cascades that promote gene transcription by nuclear factor-κB (NF-κB), activator protein 1 (AP1), and interferon regulatory factors (IRFs) and results in the production of pro-inflammatory cytokines, interferons, and other pro-inflammatory proteins ([@B3]; [@B46]). DAMPs correspond to endogenous ligands that are released by dying or damaged cells after cellular stress and can be recognized by PRRs such as membrane-bound toll-like receptors (TLRs) or cytosolic nucleotide-binding domain and leucine-rich repeat-containing (NLR), the RIG-I-like receptor (RLR), the AIM2-like receptor (ALR; [@B70]; [@B71]; [@B25]).

In the CNS, PRRs are primarily expressed by microglia, macrophages and astrocytes. These receptors are either membrane-bound and sense extracellular or endosomally located signals (TLRs) or are located within the cytoplasm and sense intracellular signals (NLRs). Recently, it was proposed that TLRs have an important role in the crosstalk between neurons and glial cells in the CNS. TLR signaling was linked to neurogenesis, it was also found to be involved in the pathogenesis of neurodegenerative diseases ([@B39]). Only cytosolic receptors are involved in the formation of inflammasomes. The inflammasome is an intracellular multimolecular complex for the activation of inflammatory caspases-1 and -11 which leads into the cleavage and secretion of IL-1β and IL-18 and cell death called -- pyroptosis ([@B69]; [@B55]). Caspases-1 and -11 both induce pyroptosis, but only caspase-1 processes IL-1β and IL-18 ([@B47]). The nucleotide binding and oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, which is composed of NLRP3, the adaptor molecule apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and the cysteine protease caspase-1, is one of the most studied inflammasomes with responses to various endogenous and exogenous danger signals ([@B56]). The priming step, that up-regulates NLPR3 pro-IL-1β gene expression, provides TLR signaling ([@B10]). Once primed, NLRP3 can respond to its stimuli and assemble the NLRP3 inflammasome. Stimuli that induce NLRP3 inflammasome assembly include ATP, pore-forming toxins, crystalline substances, nucleic acids, hyaluronan, and fungal, bacterial, or viral pathogens ([@B56]; [@B55]). It has been proposed that phagocytosis of crystalline or particulate structures triggers lysosomal destabilization and subsequent release of the lysosomal cathepsins into the cytosol, and subsequently activates NLRP3 inflammasome ([@B35]). However, it is not known yet if the cathepsins interact directly with the inflammasome or the process involves molecules activated by the cathepsins. Recent studies have revealed a role for reactive oxygen species (ROS) of mitochondrial origin in the promotion of NLRP3 inflammasome activation ([@B73]; [@B101]). Several reports showed that caspase-8 localizes and binds to ASC specks, indicating that caspase-8 is an important component of the inflammasome complex ([@B66]; [@B87]). In addition to the canonical \[lipopolysaccharide (LPS) and ATP\] NLRP3 inflammasome activation, a non-canonical inflammasome activation was described ([@B47]; [@B84]; [@B12]). Canonical inflammasomes convert procaspase-1 into the catalytically active enzyme, whereas an undefined non-canonical inflammasome promotes activation of procaspase-11 ([@B55]). The mouse caspase-11 (gene name *Casp4)* has 46% similarities to caspase-1 and is orthologous to human caspases-4 and -5 ([@B98]; [@B45]). Non canonical inflammasomes could be activated by Gram-negative, but not by Gram-positive, bacteria, indicating that a specific factor from Gram-negative bacteria -- LPS is required ([@B13]; [@B84]). In addition, caspase-11 detected intracellular LPS and some intracellular bacteria, directly mediate cell death and IL-1α secretion by a TLR4-independent mechanism ([@B33]; [@B55]). The non-canonical inflammasome pathway caspase-11 can interact with caspase-1 and forms a heterodimeric complex. It could induce a lytic cell death similarly to caspase-1; however, it cannot by itself trigger IL-1β/-18 processing ([@B99]; [@B47]). Only caspase-11-deficient mice, but not caspase-1-deficient mice were protected from endotoxic shock ([@B99]; [@B47]). The CNS is particularly sensitive to IL-1β and IL-18 signaling because multiple neural cell types in the CNS express receptors for these cytokines ([@B5]; [@B4]).

The goal of the present review is to describe recent advances in neuroinflammation and the role of stefin B in the process.

Cells of the Immune System in CNS
=================================

Microglia are CNS resident myeloid cells of embryonic hematopoietic origin and comprise approximately 12% of cells in the brain ([@B2]). Other CNS resident cells descend from neuroepithelial stem cells and are categorized as neurons and macroglia, with glia further subdivided into astrocytes and oligodendrocytes.

Astrocytes maintain CNS homeostasis and provide neuronal support in healthy conditions; moreover, astrocytes can undergo diverse phenotypic changes that may be protective or causative with regard to pathology ([@B91]). Astrocytes can produce numerous inflammatory molecules like cytokines, chemokines, growth factors, and nitric oxide (NO). Analysis of astrocyte transcriptome profiles indicates that astrocyte exposure either *in vivo* or *in vitro* to PAMPs such as LPS turns astrocyte transcriptome changes toward pro-inflammatory and potentially cytotoxic profiles ([@B36]; [@B100]). Although astrocytes may undergo diverse phenotypic changes and secrete pro-inflammatory molecules, a recent study reported that NLRP3 inflammasome was expressed and functional only in mouse brain microglia, but not in astrocytes ([@B32]). However, microglial--astrocyte interactions are important in the CNS innate immunity.

Microglia is a unique myeloid cell population, derived from primitive myeloid progenitors that arise before embryonic day 8, before vascularization or definitive hematopoiesis in the embryo ([@B27]). Its density varies by brain region, they are localized mostly in the grey matter, with the highest concentrations being found in the hippocampus, olfactory telencephalon, basal ganglia, and substantia nigra ([@B57]). Upon localization, microglia acquires a compact or ramified phenotype ([@B57]; [@B11]). In their resting state microglia have ramified morphology, and monitor the brain environment. In response to immunological stimuli or brain injury the cells are activated ([@B88]). Activated microglia acquire a compact phenotype and up-regulate several surface molecules like major histocompatibility complex (MHC) molecules, chemokine receptors and several other markers ([@B86]). Under other circumstances, however, microglia become over-activated and can induce significant and highly detrimental neurotoxic effects by the excess production of a large array of cytotoxic factors such as superoxide ([@B19]), NO ([@B72]), and tumor necrosis factor-α (TNFα; [@B59]). In some cases, microglial responses could also be protective to the CNS ([@B53]; [@B95]). Gene expression and morphological changes associated with microglial activation have been extensively studied ([@B82]). Several TLRs are expressed on the microglial membrane and signaling induced by TLR activation results in production of neurotoxicity and could contribute to the microglial response to neuronal damage. Activation of TLR2, TLR4, and TLR9 induces microglial production of NO through multiple ligands ([@B22]). TLR9 recognizes single-stranded unmethylated CpG-DNA (bacterial DNA), which stimulates an increase in the production of microglial NO and TNFα ([@B78]; [@B22]). TLR4 together with CD14 is implicated in brain inflammation and microglial activation in response to endotoxemia ([@B16]). Monocyte-derived macrophages are classified as M1, M2a, M2b, and M2c subsets ([@B28]; [@B26]). It is possible that microglia also transcribe activation-dependent genes, like macrophages. Both microglia and macrophages share several similarities, they are both myeloid-derived cells; however, there are also some differences between the two cell types. Some common markers used for microglial identification such as CD11b, CD11c, and CX3CR1, could be found in microglial cells as well as in monocytes, macrophages, and dendritic cells. The difference in the expression level of cell membrane tyrosine phosphatase CD45 may be used to discriminate CD45^low^ microglia from CD45^high^ blood-derived cells by flow cytometry ([@B90]; [@B24]). However, the signaling pathways in NLRP3 inflammasome activation are comparable between macrophages and microglia ([@B35]). Microglia clear apoptotic cells and are involved in both elimination and maintenance of synapses, they use their fine processes to monitor for dysfunctional synapses, which they are able to eliminate by phagocytosis ([@B97]). They also promote synaptic activity by secretion of brain-derived neurotrophic factor (BDNF), a molecule that is essential for learning-dependent synapse formation ([@B79]). Moreover, microglia could modulate adult neurogenesis in the brain ([@B96]). Some studies suggested that microglial cells not only have a scavenger role during development but can also promote the death of some neuronal populations ([@B68]). Several studies have reported NLRP3 activation in microglia or CNS macrophages, although NLRP3 has also been proposed to function in neurons ([@B20]; [@B83]). The activation mechanisms reported for NLRP3 activation in macrophages, such as ROS production, K^+^ eﬄux and endosomal rupture, also apply to NLRP3 activation within microglia ([@B35]; [@B40]; [@B38]). Not only caspase-1, but also caspase-11 is expressed in microglial cells and could contribute to inflammasome activation ([@B58]; [@B48]).

Cystatins in Inflammation
=========================

Cystatins were initially characterized as inhibitors of lysosomal cysteine cathepsins, however, in recent years some alternative functions for cystatins have been proposed. Cystatins possessing inhibitory function are members of three families, family I (stefins), family II (cystatins), and family III (kininogens; [@B49]; [@B94]).

The cystatins ([cyst]{.ul}eine proteinase [in]{.ul}hibitor) are reversible and tight-binding inhibitors of the papain (C1) and legumain (C13) families of cysteine proteases and have significant similarities in amino acid sequence ([@B8]; [@B9]). The inhibitory profile of a particular cystatin is rather specific, despite significant sequence homologies ([@B94]). Type 1 cystatins -- stefins are mostly intracellular cystatins present in the cytosol and the nuclei ([@B1]). They are single-chain polypeptides ∼100 amino acid residues long, are synthesized without signal peptides and do not possess any disulfide bonds or carbohydrate side-chains. Recently, we reported the mitochondrial localization of stefin B ([@B63]). Type 2 cystatins are mainly extracellular, secreted proteins. They are synthesized with 20--26 residue long signal peptides and most of them are found in physiologically relevant concentrations in body fluids ([@B1]; [@B49]; [@B94]). They contain disulphide bridges and may be phosphorylated ([@B52]). Type II cystatins also possess a second reactive site for inhibition of the C13 family of cysteine proteases (legumain; [@B6]). Cystatin C was found upregulated in the serum of patients with autoimmune diseases like systemic lupus erythematosus ([@B61]). Moreover, cystatin F was found abundant in the cells of the immune system: macrophages and dendritic cells and the cells involved in target cell killing (NK cells and cytotoxic T cells (CTLs; [@B34]; [@B74]; [@B75]). It was also found in the microglial cells and monocyte/macrophages in the CNS. Cystatin F is expressed as a di-sulfide-linked dimer ([@B14]) and translocated to endolysosomes where it regulates cathepsin activity. Cystatin F transport to endolysosomes depends on its *N*-linked glycosylation and it was reported that the secreted dimeric cystatin F could be internalized and activated by the mannose-6-phosphate receptor system ([@B18]). After proteolytic removal of its N-terminal part, cystatin F becomes a potent inhibitor of cathepsin C with the potential to regulate pro-granzyme processing and cell cytotoxicity ([@B37]). Recently, we demonstrated that cathepsin V in IL-2 stimulated NK cells could process cystatin F ([@B64]). In cytotoxic cells, cystatin F, therefore, appears as a key regulator of granzyme processing and consequently cell cytotoxicity.

Type 3 cystatins are high molecular weight (60--120 kDa) multidomain proteins and have three tandemly repeated type 2-like cystatin domains ([@B89]). The mammalian cystatins belonging to this type are the kininogens ([@B76]). Cystatins in immune cells have been reported to participate in the release of nitric oxide, phagocytosis, and expression of cytokines ([@B49]; [@B62]; [@B63]).

Stefin B and EPM1 1
===================

Stefin B belongs to the type one cystatins and is located in the cytosol, mitochondria, and nucleus where it protects cells from the detrimental release of the lysosomal cysteine cathepsins. In the nucleus, stefin B interacts with nucleosomes, specifically with histones H2A.Z, H2B, and H3 and cathepsin L ([@B15]). [@B29] has shown that only shorter procathepsin L isoforms translocate to the nucleus and stimulate processing of the CUX1 transcription factor at the G~1~/S transition of the cell cycle. Stefin B-deficient mouse embryonic fibroblasts entered S phase earlier than wild type mouse embryonic fibroblasts. In contrast, increased expression of stefin B in the nucleus delayed cell cycle progression in T98G cells. The delay in cell cycle progression was associated with the inhibition of cathepsin L in the nucleus, as judged from the decreased cleavage of the CUX1 transcription factor ([@B15]). Moreover, we have shown that stefin B overexpression in the nucleus delayed not only cell cycle progression, but also caspase activation ([@B92]). Mutations in the gene encoding stefin B (either through a multiplied repeat unit in the promoter or through point mutations in the structural gene) are present in both alleles of the gene in patients with a form of progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1; [@B81]; [@B54]; [@B80]). EPM1 is an autosomal recessively inherited neurodegenerative disease, characterized by the cerebellar granule neurons apoptosis, progressive ataxia and myoclonic epilepsy ([@B43]). In lymphoid cells of EPM1 patients, increased cathepsin activity, due to reduced expression of stefin B was reported ([@B85]), we determined increased overall cathepsin activity in untreated, as well as in classically activated stefin B-deficient bone marrow-derived macrophages (BMDMs) compared to WT cells ([@B65]).

Mouse Model of EPM1
===================

Stefin B-deficient mice develop myoclonic seizures by one month of age and progressive ataxia by six months of age ([@B80]). [@B41] reported that the removal of cathepsin B from stefin B-deficient mice greatly reduced the neuronal apoptosis, but did not rescue the ataxia and seizure phenotype. Moreover, stefin B deficiency was implicated in the impaired redox homeostasis, resulting in a pronounced oxidative stress-induced cell death and neurodegeneration ([@B60]). Thymocytes from stefin B deficient mice were significantly more sensitive to apoptosis induced with the inhibitor of protein kinase C, staurosporin ([@B50]). Manninen et al. examined in detail the spatiotemporal dynamics of the brain atrophy in stefin B-deficient mice ([@B67]). They showed progressive but non-uniform volume loss of the stefin B-deficient mouse brains, indicating that different neuronal populations possess distinct sensitivity to the damage, as a consequence of stefin B deficiency. The authors suggested that the white matter damage in the brain of stefin B-deficient mice was secondary to glial activation and neurodegeneration ([@B67]). Another report showed that the early microglial activation precedes neuronal loss in the brain of the stefin B deficient mice, implying a role of the inhibitor at the cross-talk between microglia and cerebellar cells ([@B93]).

[@B44] analyzed the gene expression changes in the cerebellum of pre-symptomatic and symptomatic stefin B -deficient mice and in cultured stefin B-deficient cerebellar granule cells. Already in the cerebellum of pre-symptomatic stefin B-deficient mice (7 days after the birth), multiple changes in gene expression related to synapse maturation, development, and function during postnatal maturation were observed. More prominent changes were reported in the GABAergic signaling pathway ([@B44]). GABA plays a central role in controlling neuronal development and connectivity and defective GABAergic signaling in the cerebellum of stefin B deficient mice underlines a mechanism for ataxia in these mice ([@B31]). At a later stage (30 days after the birth), in symptomatic stefin B-deficient mice, the authors reported the upregulation of immune response genes, in line with the results showing early glial activation that preceded neuronal degeneration ([@B93]). Moreover, [@B44], reported the upregulation of the genes involved in cell cycle progression, in stefin B-deficient granule neurons. We have shown that the interactions of stefin B with cathepsin L in the nucleus influence cell cycle progression into the S phase ([@B15]). We cannot exclude the possibility that the impaired cathepsin regulation in the synapses could lead to morphological and functional changes observed in stefin B-deficient mice ([@B44]). For example, cathepsin B-like immunoreactivity was observed at synaptic sites and myristoylated-alanine-rich C-kinase substrate (MARCKS), a known substrate of cathepsin B, was specifically degraded in response to intense NMDA receptor stimulation ([@B30]). Previously, we reported the increased cleavage of MARCKS in the brains and macrophages of stefin B-deficient mice, when compared to cells and tissue from control wild-type animals ([@B51]).

Stefin B, EPM1, and Innate Immune Response
==========================================

The increased expression of inflammatory genes indicates that neuro-inflammation, together with neuronal dysfunction, plays a crucial role in pathology of EPM1. Pro-inflammatory chemokines and cytokines, highly expressed in symptomatic stefin B-deficient mice were reported to lower the seizure threshold and may thus contribute to recurrent excitation in epilepsy ([@B21]). [@B77] reported significantly higher stefin B mRNA expression in microglia than in neurons or astrocytes, which is in line with our observation that stefin B is highly upregulated in activated macrophages ([@B65]). In pre-symptomatic stefin B-deficient mice compared to control animals the ratio of M1/M2 microglia is skewed towards M2 type, but towards M1 type in symptomatic mice. In addition, a heightened expression of both pro-inflammatory inducible nitric oxide synthase (iNOS), anti-inflammatory arginase 1 (ARG1) and chemokine release was detected ([@B77]). Interestingly, MHCII surface expression was suppressed. We have reported that IFN-γ and LPS-activated stefin B-deficient BMDMs produced higher amounts of NO, and expressed more iNOS than WT BMDMs. IL-10 is a potent anti-inflammatory cytokine that is crucial for dampening the inflammatory response after pathogen invasion and acts to protect the host from excessive inflammation ([@B23]). We showed decreased expression of IL-10 in BMDMs of stefin B deficient mice, due to impaired STAT3 signaling ([@B65]). IL-10 plays an essential role in mediating inflammatory processes not only in the cells of immune system, but also in the brain ([@B102]). It has been demonstrated that it increases the survival of cerebellar granule cells by blocking caspase-3-like activity ([@B7]). It is tempting to speculate that the decreased IL-10 expression in stefin B-deficient mice could contribute to the increased apoptosis in the cerebellum in EPM1.

In the developing mouse cerebellum, Purkinje cells die and a majority of these neurons are engulfed by microglial cells. Interestingly, apoptosis of Purkinje cells in the cerebellum was strongly reduced by selective elimination of microglia and superoxide produced by microglia cells ([@B68]). In our recent work we showed that stefin B-deficient mice were significantly more sensitive to the lethal LPS-induced endotoxemia due to increased caspase-11 expression. The increased caspase-11 gene expression and better caspase-1 and -11 processing determined in stefin B-deficient BMDMs resulted in enhanced IL-1β and IL-18 processing and secretion (**Figure [1](#F1){ref-type="fig"}**). The increased cathepsin activity determined in stefin B deficient BMDMs was not essential for inflammasome activation, since treatment of BMDMs with the cathepsin inhibitor E-64d did not influence caspase-1 activation and IL-1β secretion. Upon LPS stimulation, stefin B was targeted to mitochondria, and the lack of stefin B resulted in the increased destabilization of mitochondrial membrane potential and mitochondrial ROS generation ([@B63]). The induction of ROS in microglia may therefore play an important role in non-canonical inflammasome activation and cell death in the cerebellum in disease.

![**Proposed model for the role of stefin B in non canonical inflammasome activation**. Upon lipopolysaccharide (LPS) stimulation stefin B is translocated from cytosol into mitochondria and protects mitochondrial membrane integrity. Stefin B deficiency resulted in the breakdown of mitochondria membrane potential and increased mtROS generation. The consequence of the increased mtROS detected in stefin B-deficient bone marrow-derived macrophages (BMDMs) upon LPS stimulation, was the increased nuclear factor-κB (NF-κB) activation and caspase-11 expression. Increased caspase-11 expression resulted in increased inflammasome activation and pro-inflammatory IL-1β and IL-18 secretion.](fncel-09-00458-g001){#F1}

Conclusion
==========

This review summarizes recent discoveries that may contribute to the understanding of the role of stefin B in neuro-inflammation. Several studies, each from a different angle, have contributed a piece of the puzzle, a process we are trying to understand. Stefin B-deficient mice have proven to be a valuable tool to explore the function of the protein in the pathology of disease. During the past couple of years, several new data from microarray experiments, histology, as well as magnetic resonance imaging have revealed that neuro-inflammation is an essential process in the pathology of EPM1. Biochemical experiments in macrophages have contributed some hints regarding the signaling pathways in inflammasome activation. Signaling pathways in macrophages were compared to the ones in microglia and the expression of caspase-11 was strongly induced by activation of rat glial cells, as well as in astrocytes, with interferon-γ and LPS ([@B42]). The expression of caspase-11 in microglia may play an important role in non-canonical inflammasome activation and cell death in the cerebellum in disease. However, some questions still remain and some more pieces need to be added to complete the whole picture. Additional experiments will reveal if the inflammasome activation and caspase-11 expression are part of the pathology of EPM1.
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